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Abstract
Background: Colorectal cancer (CRC) is the third major cause of cancer related deaths in the world. 5-fluorouracil (5-FU) is
widely used for the treatment of colorectal cancer but as a single-agent renders low response rates. Choline kinase alpha
(ChoKa), an enzyme that plays a role in cell proliferation and transformation, has been reported overexpressed in many
different tumors, including colorectal tumors. ChoKa inhibitors have recently entered clinical trials as a novel antitumor
strategy.
Methodology/Principal Findings: ChoKa specific inhibitors, MN58b and TCD-717, have demonstrated a potent antitumoral
activity both in vitro and in vivo against several tumor-derived cell line xenografts including CRC-derived cell lines. The effect
of ChoKa inhibitors in combination with 5-FU as a new alternative for the treatment of colon tumors has been investigated
both in vitro in CRC-tumour derived cell lines, and in vivo in mouse xenografts models. The effects on thymidilate synthase
(TS) and thymidine kinase (TK1) levels, two enzymes known to play an essential role in the mechanism of action of 5-FU,
were analyzed by western blotting and quantitative PCR analysis. The combination of 5-FU with ChoKa inhibitors resulted in
a synergistic effect in vitro in three different human colon cancer cell lines, and in vivo against human colon xenografts in
nude mice. ChoKa inhibitors modulate the expression levels of TS and TK1 through inhibition of E2F production, providing a
rational for its mechanism of action.
Conclusion/Significance: Our data suggest that both drugs in combination display a synergistic antitumoral effect due to
ChoKa inhibitors-driven modulation of the metabolization of 5-FU. The clinical relevance of these findings is strongly
supported since TCD-717 has recently entered Phase I clinical trials against solid tumors.
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Introduction
Colorectal cancer (CRC) is the first most prevalent cancer and is
the second cause of cancer death in Europe with about 212.000
deaths every year [1]. The most studied drug in CRC is the
antimetabolite 5-fluorouracil (5-FU), developed over 50 years ago
[2]. 5-FU is an analog of uracil with a fluorine atom. Its
mechanism of cytotoxicity consists in misincorporation of fluor-
onucleotides into RNA and DNA but the main toxic effects are
mediated by the inhibition of the nucleotide synthetic enzyme
thymidylate synthase (TS). 5-FU is widely used in the treatment of
a range of cancers, including CRC, breast and head and neck
cancers [3,4]. Response rates for 5-FU based chemotherapy as a
first-line treatment for advanced CRC cancer are only 10–15%
[5]. Combination of 5-FU with new cytotoxic drugs such as
oxaliplatin and irinotecan has improved the response rates to 40–
50% [6,7]. Furthermore, novel biological agents such as the
monoclonal antibodies cetuximab and bevacizumab have demon-
strated additional benefits in patients with metastatic disease [8,9].
Thus, this approach is achieving important improvements, and
promotes new therapeutic strategies based on combinatorial
treatments.
Choline kinase alpha (ChoKa), the first enzyme in the Kennedy
pathway, is responsible for the synthesis of the major phospholipid
of the plasma membranes, phosphatidylcholine (PC). Several
studies have demonstrated that ChoKa plays an important role in
cell transformation and induces in vivo tumorogenesis [10,11].
Furthermore, ChoKa is overexpressed in colon, breast, lung,
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prostate, ovary and hematological tumors [11–16]. Based on these
observations, ChoKa has been used as a novel molecular target to
develop a new antitumoral strategy. ChoKa inhibitors (ChoKIs)
are derivates of the Hemicolinium-3 (HC3) structure, a known
choline kinase inhibitor with a high neurotoxicity in vivo [17–19].
MN58b [20,21] was identified as a first generation HC3 derivate
with potent antiproliferative activity in vitro and efficient antitu-
moral activity in vivo in nude mice systems including colon
xenografts [10,21]. MN58b has been used as a model for a new
generation of compounds, and a lead molecule to study the
mechanism of action of this novel class of antitumor drugs.
A second generation of ChoKa inhibitors has been synthesized
to improve the tolerability of ChoKa inhibitors in mice. TCD-717
has been selected among several molecules because it provided the
best results in vitro and in vivo (unpublished results). ChoKa
inhibitors are highly specific drugs for tumor cells, since primary
cells are reversibly arrested in G1 and are able to recover their
growth kinetics once the drug is removed. However, tumor cells
are triggered to cell death concomitant to an increase in the
intracellular levels of ceramides [22,23]. Both drugs, MN58b and
TCD-717, are derived from Hemicolinium-3, and as such they are
both considered competitive inhibitors with choline at the choline
binding pocket [24–26].
It has been described that the combined use of a choline kinase-
specific siRNA and 5-FU, results in a synergistic effect on the
reduction of cell proliferation of breast cancer cells [27]. The aim
of the present study was to investigate the antitumor efficacy of the
combined administration of chemical ChoKa inhibitors and 5-FU,
searching for an alternative treatment that would allow to improve
5-FU rate response in CRC treatment and reduce its associated
toxicity. The clinical relevance of this new treatment is strongly
supported since TCD-717 has been recently approved to enter
clinical trials against solid tumours (http://clinicaltrials.gov/ct2/
show/NCT01215864).
Results
ChoKa levels in human derived colorectal cancer cell
lines
ChoKa levels were analyzed in the three colon cancer cell lines
used in this study, DLD-1, HT29 and SW620 versus a non
tumoral colorectal cell line CCD-841. Figure 1 shows that ChoKa
levels are about 20–30 times higher than the primary cell line. This
result is in keeping with previous analysis of ChoKa expression in
tumor samples compared with matched normal tissues from the
same patient [11], and provides a rational for the potential use of
ChoKa inhibitors in the clinic in combination with standard
chemotherapy.
ChoKa inhibitors synergizes with 5-FU promoting cell
death of colon cancer cells
The effect on proliferation of ChoKa inhibitors in combination
with 5-FU was determined in the three colorectal cancer cell lines:
DLD-1, HT29 and SW620. To estimate the appropriate
concentrations for each compound, cells were treated with a wide
range of concentrations based on their respective IC50, alone or in
combination. Concentrations used were from 1 to 6 mM (MN58b
and TCD717) and 2 to 8.5 mM 5FU both as concomitant and
sequential treatments (Fig S1). The best combination to achieve an
efficient synergism as antiproliferative drugs was a sequential
treatment initiated by a ChoKa inhibitor and followed by 5-FU.
The inhibitory effect was quantified by the MTT assay, and the
inhibition rates were analyzed by the method of Chou and Talalay
and combination indexes (CIs) estimated according to the
Calcusyn program [28]. Plots were obtained when the ChoKa
inhibitors TCD-717 and MN58b were combined with 5-FU in
DLD-1, HT29 and SW620 cell lines (Figure S1). CIs and a
representative figure of each different CRC cell line by the
sequential combination of ChoKa inhibitors and 5-FU are shown
(Figure 2).
The effect of this combination was investigated, and cell cycle
distribution induced by TCD-717 and 5-FU alone or in
combination analyzed (Figure 3). Flow cytometry analysis showed
a significant induction of cell death after treatment with ChoKIs
with a further increase in combination with 5-FU, indicating that
the combined treatment had a stronger effect than individual
treatments. Previous studies demonstrated that tumour cells are
sensitive to ChoKa inhibitors if exposed at G1 phase, but become
insensitive in S phase [23]. 5-FU exposure induced S phase
accumulation, but the combined treatment drastically reduced S
phase accumulation and increased cell death rates. These results
support the requirement of a sequential treatment initiated with
ChoKa inhibitors explaining the lack of synergism observed with
alternative schedules of treatment.
In vivo synergism of ChoKa inhibitors and 5-FU in nude
mice
The effects of combinatorial treatments of ChoKa inhibitors
and 5-FU on the in vivo tumor growth of DLD-1 and SW620
xenografts in nude mice were next investigated. DLD-1 xenografts
were inoculated into athymic mice and when tumours reached the
standard volume of around 0.2 cm3, mice were randomly divided
into four groups (10 tumors/group) and treated following the next
schedule: ChoKa inhibitors were administered at 2 mg/kg/day
three times a week during 3 weeks, and 5-FU was administered at
40 mg/kg/day twice a week for 3 weeks. Tumour growth was
recorded after the initiation of treatment. Tumour volumes were
reduced in all treated groups regardless of the treatment,
compared with those of control, untreated mice (Figure 4). Tumor
growth of the combination groups in each experiment was
significantly smaller than those treated with ChoKa inhibitors or
5-FU alone (p-values,0.05) indicating a strong reduction of tumor
volume in the combination schedules.
Figure 1. ChoKa expression levels in DLD-1, HT29 and SW620
cell lines by western blot. ChoKa protein levels of three colorectal
tumor cell lines, DLD-1, HT29 and SW620 have been compared respect
to the non tumoral colorectal cell line CCD-841. Below the western it is
represented quantification levels (ChoKa/tubulin).
doi:10.1371/journal.pone.0064961.g001
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As a validation, SW620 xenografts were also investigated
following an identical schedule with a combination of TCD-717
and 5-FU. A statistically significant effect was also observed in the
combination treatment (Figure 4).
ChoKa inhibitors modulate the expression levels of key
enzymes involved in the metabolism of 5-FU
To elucidate the mechanism of this synergistic effect of ChoKa
inhibitors and 5-FU, we examined the effect of ChoKa inhibitors
on the expression levels of key enzymes in the metabolic pathway
of 5-FU such as thymidylate synthase (TS) and thymidine kinase
(TK1). SW620 cells were treated with increasing concentrations of
ChoKa inhibitors from 2 to 10 mM (Figure 5A) showing a dosage-
dependent decrease in the levels of these proteins. Next, SW620,
HT29 and DLD-1 were treated with ChoKa inhibitors (TCD-717
6 and 10 mM, MN58b 10 and 15 mM) and 5-FU (5.5 mM), alone
or in sequential combination to determine the effects on the
expression levels of these enzymes (Figure 5B). Free (active form)
and ternary complex (inactive form) of TS and TK1 were
analyzed by western blotting. As expected, cells treated with 5-FU
showed both the TS ternary complex (upper band) and the free TS
(lower band). ChoKa inhibitors induced a significant down-
regulation of both free TS (active form) and ternary complex
(inactive form), as well as TK1 (Figure 5B). Thus the sequential
combination of ChoKa inhibitors and 5-FU induced both
mechanisms of inactivation, decreased formation of ternary
complex and a significant down-regulation of TS active (free
form). In addition, ChoKIs decreased TK1 levels, affecting also
Figure 2. Effect on cell viability of ChoKa inhibitors and 5-FU in DLD-1, HT29 and SW620 cell lines. 66103 tumor cells were cultured in
96 well plates. After 24 h incubation, cells were exposed to TCD-717(left panels) for 24 h or MN58b (right panels) for 9 h. Thereafter the medium was
changed for medium containing 5-FU for 60 h in plates previously treated with MN58b and for 24 h in plates treated with TCD-717. Cell viability was
evaluated by MTT assay and represented as percentage of control, untreated cells. CI value in each case is the mean of three independent
experiments, each performed in quadruplicates. CI,1 indicates a synergistic effect. A representative experiment of three independent experiments is
shown.
doi:10.1371/journal.pone.0064961.g002
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Figure 3. Cell cycle distribution in DLD-1 and SW620 from TCD-717 and 5-FU treatment, alone or in combination. 2,56105 DLD-1 and
SW620 cell lines were seeded in 6 well plates and incubated for 24 h with TCD-717 followed by 5-FU for 24 h alone or in combination. Combination
of the two drugs increased cell death compared to the two drugs alone. Tables under the graphics indicate the percentage of the different phases of
cell cycle when we treat with TCD-717 and 5-FU alone or in combination. *p,0.05 compared the different cell cycle phases vs. control.
doi:10.1371/journal.pone.0064961.g003
Figure 4. Tumour growth inhibition by combination of ChoKa inhibitors and 5-FU on DLD-1 and SW620 xenografts in athymic nude
mice. Mice were exposed to 2 mg/kg/day of ChoKa inhibitors three days a week and 40 mg/kg/day of 5-FU two days a week in combination or alone
during 3 weeks. Tumor growth inhibition rate is shown below each experiment. (A) DLD-1 tumors treated with MN58b as ChoKa inhibitor and 5-FU.
(B) DLD-1 tumors treated with TCD-717. (C) SW620 tumors exposed to TCD-717 and 5-FU.
doi:10.1371/journal.pone.0064961.g004
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the mechanism associated to 5-FU resistance. This effect could
explain the mechanism of synergism between both drugs.
Both TK1 and TS have been shown to be under transcriptional
control of E2F1 [29,30]. Thus we investigated whether the drastic
reduction in the levels of TK1 an TS after ChoK inhibition was
mediated by an effect on the levels of this transcription factor. As
shown in Figure 5C, in all three cell lines investigated, a drastic
reduction in the levels of E2F1 was observed consistent with its
role as regulator of TS and TK1 synthesis.
Next, to investigate the potential induction of apoptosis after
ChoK inibition, as a hallmark of apoptosis, the levels of PARP
were analyzed under similar conditions, and a drastic reduction
was observed in PARP levels in SW620 (Figure 6A), HT29
(Figure 6B) and DLD-1 (Figure 6C) cell lines after treatment with
the combination schedule. PARP is a protein implicated in DNA
repair and its decrease has a similar physiological meaning to that
of its cleavage because reduced levels of PARP avoid DNA repair
and cells are triggered to apoptosis engagement.
HT29 and SW620 cells were also transfected with a specific
siRNA-ChoKa. As shown in Figure 6D, similar results were
obtained to those of ChoKa pharmacological inhibition, with a
drastic reduction in PARP levels, an indication of specificity due to
ChoKa inhibition.
As an additional evidence of the induction of apoptosis after
ChoK inhibitors in colon cancer cells, two alternative methods for
the initiation of the apoptotic signaling machinery were used.
Caspase 3 activity and cleavage was readily detected after MN58b
treatment of HT29 cells (Figure 6E). Downregulation of ChoKa
expression by specific siRNA also increased caspase activity, a
further support of the specificity of this effect based on reduction of
ChoKa activity (Figure 6F). Thus, ChoK inhibitors are able to
induce apoptosis by the activation of caspase 3.
Finally, TS levels were analyzed in tumors generated from the in
vivo xenograft model DLD-1 after treatment with MN58b and 5-
FU and compared to control, untreated mice (Figure 7). A
statistically significant reduction in TS levels (both total and active
protein) was observed in tumors treated with MN58b alone or in
combination with 5-FU, while no significant difference was found
in the tumors from mice treated with 5-FU alone.
Down-regulation of mRNA levels of TS and TK1 gene
after treatment with ChoKa inhibitors and 5FU in DLD-1,
SW620 and HT29 cells
Preclinical and clinical studies have demonstrated that TS
expression is determinant of 5-FU sensitivity and clinical outcome
[31,32]. In keeping with these results, gene amplification of TS
Figure 5. Levels of TS and TK1 in SW620, HT29 and DLD-1 cell lines determined by Western blot analysis. 2,56105 DLD-1, HT29 and
SW620 cell lines were seeded in 6 well plates and incubated for 24 h. (A) SW620 cell line was exposed to increased concentrations of ChoKa inhibitors
for 24 h. (B) SW620, HT29 and DLD-1 cell lines were exposed to two concentrations of ChoKa inhibitors [TCD-717: 6 mM (left line) or 10 mM (right line);
MN58b: 10 mM (left line) or 15 mM (right line)]. Where indicated, medium was removed after treatment with ChoKa inhibitors as above and changed
for fresh medium with 5.5 mM 5-FU for an additional 24 h. Protein expression was analyzed by western blot using monoclonal anti-thymidilate
Synthase TS106 clone for TS and monoclonal anti-thymidine kinase clone F12 for TK1. The figure shows on the top a representative blot, at the
bottom protein levels (total TS, active TS, and TK1/tubulin) calculated by the mean 6 SEM of three independent experiments. (C) 2,56105 SW620,
HT29 and DLD-1 cell lines were seeded in 6 well plates and incubated for 24 h. (A) SW620, (B) HT29 and (C) DLD-1 cell lines were exposed to two
concentrations of ChoKa inhibitors [TCD-717: 6 mM (left line) or 10 mM (right line); MN58b: 10 mM (left line) or 15 mM (right line)]. Where indicated,
medium was removed after treatment with ChoKa inhibitors as above and changed for fresh medium with 5.5 mM 5-FU for an additional 24 h.
Protein expression was analyzed by western blot using anti-E2F1. The figure shows on the top a representative blot, at the bottom protein levels
(E2F1/GAPDH) calculated by the mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0064961.g005
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with consequent increases in TS mRNA and protein, has been
observed in cell lines that are resistant to 5-FU [31,33,34].
Based on the above results, SW620, HT29 and DLD-1 cells
were treated with MN58b and TCD-717 for 24 h. Treatment with
ChoKa inhibitors resulted in a significant down-regulation of both
TS and TK1 mRNA levels as determined by real time Q-PCR
assay using the specific probes Hs00426591_m1 for TS and
Hs01062125_m1 for TK1 (Figure 8). These results indicate that
the down modulation in the protein levels of TS and TK1 induced
by ChoKa inhibitors results from a drastic reduction at the
transcriptional level, with a significant effect in both TS, and its
salvage pathway mediated by TK1. Since the levels of E2F1 were
also drastically reduced, it is reasonable to propose that this
transcription factor is responsible for the observed effects on TS
and TK1 inhibition as previously described [29,30].
The above results would be consistent with a general effect on
gene transcription induced by ChoKa inhibitors. To test for this
possibility, mRNA levels of other proteins also involved in 5-FU
mechanism of action were investigated. Contrary to what was
observed with TS or TK1, uridine phosphorylase (UPP1) was
increased after treatment with ChoKa inhibitors (Figure 9). This
elevation may be physiologically relevant because UPP1 is
responsible for the transformation of 5-FU to an intermediate
metabolite that will be converted into the active metabolites
fluorouridine triphosphate (FUTP) and fluorodeoxyuridine tri-
phosphate (FdUTP). Thus, the effects observed on E2F1, TS and
TK1 do not respond to a general, non-specific effect on gene
transcription.
Effects of ChoKa inhibitors on MAPK, AKT signaling and
ceramides levels
As previously described by us and Chesney’s group [40–42]
inhibition of ChoKa has an effect on the MAPK kinase and AKT
signaling pathways with a drastic reduction in the phosphorylated
forms in several cell types. In keeping with these results, when
SW620 cells were treated with ChoKa inhibitors, a drastic
reduction in both p42/p44 was observed (Figure 10A). However,
in contrast with previous reports on other cell lines, no significant
Figure 6. Induction of apoptosis in SW620, HT29 and DLD-1 cell lines after treatment with ChoKIs. (A–C) SW620, HT29 and DLD-1 cells
were seeded as described under Material and Methods and treated with two concentrations of ChoKa inhibitors [TCD-717: 6 mM (left line) or 10 mM
(right line); MN58b: 10 mM (left line) or 15 mM (right line)] for 24 h and, where indicated, with 5.5 mM 5-FU or vehicle for an additional 24 h. Protein
expression was analyzed by Western blot using polyclonal antibody anti-PARP. Behind each graph, data shows protein levels (PARP/GAPDH)
calculated by the mean6 SEM of three independent experiments. (A) SW620. (B) HT29. (C) DLD-1. (D) PARP and ChoKa expression levels in HT29 and
SW620 cell lines transfected with a specific ChoKa siRNA determined by Western blot analysis or a control scramble siRNA (scr). Protein expression
was analyzed by Western blot using ChoKa monoclonal antibody and polyclonal antibody anti-PARP. Below each Western the ratio PARP/Tubulin is
represented. (E) Caspase 3 activity (upper panel) and its cleavage (lower panel) were determined in HT29 cells after treatment with MN58b for 24 h.
(F) Caspase 3 enzymatic activity was also measured after transfection of HT29 cells with a ChoKa specific siRNA or a control siRNA (scr) for 48 h.
Western blot represents the levels of ChoKa after transfection and its relative reduction normalized to GAPDH levels.
doi:10.1371/journal.pone.0064961.g006
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effect was observed in the phosphorylation of pAKT-Ser473
(Figure 10B). Furthermore, no effect on either signaling pathway
was observed by treatment of SW620 cells with 5-FU alone, and
no significant modification of the effects observed when cells were
treated with ChoKa inhibitors was observed under combination
conditions.
Finally, generation of ceramides has been observed specifically
in Jurkat cells after treatment with MN58B while no significant
increase was observed in human primary lymphocytes [22]. This
may be responsible for the induction of apoptosis in this cellular
system and could also explain the observed synergism in this study.
However, no effect on ceramides levels were observed after 5-FU
treatment alone nor after combinatorial schedules with MN58B
and 5-FU (Figure 10B), excluding this mechanism as responsible
for the synergism observed when 5-FU was combined with ChoK
inhibitors.
Discussion
Colon cancer is one of the most common causes of death from
cancer worldwide. The standard treatment for CRC is based on 5-
FU as first-line usually in combination with other cytotoxic drugs
such as oxaliplatin or the topoisomerase I inhibitor CPT-11
(Irinotecan) [33–35].
A better knowledge of the molecular biology of CRC tumors
has changed management of CRC patients, with the status of K-
Ras mutations being a critical decision-making issue. Numerous
clinical trials are in progress to improve schedules for CRC
patients, as for many other types of cancer. However, the low rates
of curative treatments available makes still necessary to explore
new therapeutic approaches to achieve better rates in survival. In
this sense, a very active search for novel treatments based on
combinatorial chemotherapy and targeted therapy has generated
new promising alternatives. This strategy is based on schedules
that have raised response rates from 10-15% with 5-FU alone to
40–50% in combination chemotherapy [6,7].
Targeted therapy is a treatment with a focused mechanism that
specifically acts interfering a well-defined target or biological
pathway [36]. Currently, these new approaches constitute a real
promise for improved management and outcome of cancer
patients, since it specifically acts against cancer cells and therefore
should have less side effects than other types of therapeutic
treatments.
ChoKa is overexpressed in a large variety of human tumors
including colorectal cancer [11–16]. Increased levels of total
choline metabolites, including phosphocholine, the product of
ChoK activity, is also a common feature of many types of tumors
[37]. Therefore, ChoKa is a novel interesting target for the
development of cancer therapies. As a consequence, ChoKa
inhibitors have been synthesized to specifically interfere with its
activity [10,18,20,21].
The combination of siRNA-ChoK with 5-FU in breast cancer
cells has shown a reduction of cell viability and proliferation [27].
However, this treatment relies on the use of a siRNA which is not
Figure 7. TS expression levels in tumor tissues from DLD-1 xenografts after treatment with MN58b plus 5-FU. Mice were inoculated
with DLD-1 cells as indicated under Materials and Methods and either left untreated, or treated with MN58b or 5-FU alone or in combination. A) TS
expression levels of each experiment group: Control, MN58b, 5-FU and combination group. Tubulin was used as loading control. B) Graph represents
mean protein levels as TS/tubulin ratios for each group. Black bars represent total TS/tubulin values; Grey bars represent TS active values. (*)
Statistically significant (p,0.05), compared to control group.
doi:10.1371/journal.pone.0064961.g007
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transported to the target cells in vivo in an efficient manner. Here,
we use two chemical inhibitors specifically designed against
ChoKa (MN58b and TCD-717) with high potency against tumor
cells in vitro and in vivo, to explore the effect of the combination of
5-FU and this new targeted therapeutic approach to improve
current CRC treatments. A strong synergistic antitumoral effect
when 5-FU and ChoKa inhibitors were used in combination
against several CRC cell lines is reported.
Previous reports from our group demonstrate that induction of
apoptosis by inhibition of ChoKa is related to the specific
generation of ceramides in tumor cells [22,23]. A dramatic
difference in the response to specific ChoKa inhibitors has been
observed between normal and tumor cells. Whereas blockage of de
novo phosphocholine (PCho) synthesis by MN58b in primary cells
induces Retinoblastoma (Rb) dephosphorylation and results in
reversible cell cycle arrest in G0/G1 phase, tumor cells suffer a
drastic wobble in the metabolism of main membrane lipids
phosphatidylcholine and sphingomyelin, resulting in a significant
increase in the intracellular levels of ceramides that promotes
apoptosis [22,23]. These initial experiments have been reproduced
in additional cell types including colon cancer derived cell lines
(data not shown). Additional evidence has been reported that
indicates a clear inhibition of the PI3K/AKT and ERK signaling
pathways by ChoK inhibitors [38,39,40]. However, in the cellar
systems used in this study, neither MAPK nor AKT signaling or
ceramides generation are significantly altered by 5-FU treatment
alone. No significant effect is observed either when cells were
treated with the combinatorial regimes that showed a potent
synergism both under in vitro or in vivo conditions. These results
altogether indicate that the previous effects reported on the
mechanisms of action of ChoKa inhibitors either on MAPK, AKT
and ceramides signaling are not responsible for the synergistic
effect observed in colon cancer cells when combining ChoKa
inhibitors and 5-FU.
Here we have further investigated the mechanism of the
synergism of ChoK inhibitors and 5-FU for a better understanding
and improvement of its potential use in the clinic. TS protein has a
central role in the biosynthesis of thymidylate, an essential
precursor for DNA synthesis [41]. Some studies have shown that
TS protein levels are higher in several tumors tissues compared
with their normal counterparts [42]. Furthermore, high TS levels
are associated with poor prognosis in these cancers [43–45].
Another critical enzyme for thymidine metabolism is TK1 which
increased activity represents a potential mechanism of resistance to
5-FU [46].
Figure 8. Levels of TS and TK1 in SW620, HT29 and DLD-1 cell lines determined by RT-qPCR. 2,56105 DLD-1, HT29 and SW620 cell lines
were seeded in 6 well plates and incubated under optimal conditions for 24 h. Next, cells were exposed to different concentrations of ChoKa
inhibitors for 24 h. Levels of TS and TK1 were analyzed by RT-qPCR as described under Materials and Methods. 18S was used as the endogenous
control for normalisation.
doi:10.1371/journal.pone.0064961.g008
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Here, we demonstrate that ChoKa inhibitors induce a strong
down modulation of the levels of both TS and TK1, contributing
to the induction of apoptosis triggered by 5-FU treatment. Thus,
the mechanistic basis for the observed synergism seems to rely on
the finding that ChoKa inhibitors are modulating the levels of TS
and TK1 enzymes which are related to 5-FU metabolization.
These effects were observed in all three cell lines tested, a strong
support to the given explanation on the effects on TS and TK1.
Furthermore, IC50 values of ChoKIs for all cell lines were found
similar in a set of colon cancer derived cells lines regardless of the
p53 or K-Ras status. Thus, DLD-1 (wild type p53 and mutated K-
Ras, IC50 = 2.3 mM), SW620 (mutated p53 and mutated K-Ras,
IC50 = 3.5 mM), HT29 (mutated p53 and wild type K-Ras,
IC50 = 1.8 mM), and HCT116 cells (wild type p53 and mutated
K-Ras, IC50 = 2.5 mM) showed very similar IC50 values to TCD-
717 treatment.
TS is a key enzyme in the synthesis of DNA and the target
enzyme of 5-FU. Several studies demonstrate that the expression
levels of TS in the tumoural tissue predicts overall survival for
colon cancer and correlates with resistance to 5-FU [47,48].
Acquired resistance to 5-FU is caused by overproduction of TS
resulting from gene amplification. The free form is active and its
expression is inversely correlated with the drug sensitivity in
several human cancers [48–50].
As an attempt to understand the mechanism by which ChoKa
inhibitors control the transcriptional levels of TS and TK1, we
have found that its transcriptional regulator, E2F1, is also
drastically reduced after treatment with ChoKa inhibitors.
Although this explains the observed effects on TS and TK1
expression levels, it is an intringuing observation, but it seems that
it is not related to a general inhibitory effect on transcription since
other enzymes involved in 5-FU metabolization such as UPP1 is
not affected in a similar manner. Other enzymes are also not
inhibited but induced under similar conditions (data not shown)
further supporting a specific role of E2F1 downmodulation in the
regulation of TS and TK1 synthesis and the synergism found
between ChoKa inhibitors and 5-FU.
The implication of ChoKa inhibitors in the mechanism of
action of 5-FU shown here is in keeping with the observed optimal
sequential schedule, since treating cells with ChoKa inhibitors first
improve the down-regulation of the ternary complex formed by 5-
FU. Thus, reducing the enzymes responsible for 5-FU inactivation
with ChoKa inhibitors potentiates 5-FU efficacy. ChoKa inhib-
itors decrease TS protein levels, though the remaining protein is
still active. When cells are treated with 5-FU, the remaining active
TS form is inactivated, forms the ternary complex avoiding
thymidine formation and driving to DNA damage. Thus, with this
schedule TS activity is modulated following two different
mechanisms, down-regulation of gene expression and inactivation
of the protein. However, treating with 5-FU results only in a
partial inactivation of the enzyme.
One of the major problems for the success of chemotherapy is
drug resistance. Regarding 5-FU resistance, a salvage pathway has
been reported in which TK1 plays an important role [48]. We
demonstrate that ChoKa inhibitors not only promote 5-FU action
by down-regulating the expression of TS, but also block the
salvage pathway by down-regulating TK1, preventing dTMP
synthesis and its incorporation into DNA.
Our results provide the basis to support a new therapy focused on
the combination of ChoKa inhibitors, which are already in Phase I
clinical trials, and 5-FU as a new approach for colorectal cancer
patients. In addition, this study suggests a promising role for ChoKa
inhibitors as a new treatment for patients who had failed 5-FU
chemotherapy or display high expression levels of TS or TK1. This
Figure 9. UPP1 mRNA in SW620, HT29 and DLD-1 cell lines. 2,56105 DLD-1, HT29 and SW620 cell lines were seeded in 6 well plates and
incubated 24 h under standard conditions. Thereafter, cells were treated with ChoKa inhibitors, TCD-717 (6 and 10 mM) and MN58b (10 and 15 mM)
during 24 h. 18S was used as an endogenous control.
doi:10.1371/journal.pone.0064961.g009
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strategy may also be used in other types of pathologies where 5-FU
constitutes the basis for chemotherapeutic intervention.
Materials and Methods
Cell lines and cell proliferation assays
Proliferation studies of MN58b, TCD-717 and 5-FU were
determinate using DLD-1, HT29, SW620 and HCT116 CRC cell
lines and the non-tumourigenic CCD-841 cell line, all were
purchased from the ATCC (Manassas VA, USA). HT29 and
SW620 were maintained in DMEM, CCD-841 in MEM,
HCT116 in McCoy’s medium, and DLD-1 in RPMI1640,
supplemented with 10% fetal bovine serum. 6000 cells/well were
seeded into 96- well flat-bottom plates (BD, Falcon, Bioscience,
San Jose, CA, USA) and incubated for 24 h under standard
Figure 10. Effects of ChoK inhibition on p44/p42 MAPK levels and ceramide levels. (A) 2,56105 SW620 cells were seeded in 6 well plates
and incubated for 24 h and exposed to two concentrations of ChoKa inhibitors [TCD-717: 6 mM (left line) or 10 mM (right line); MN58b: 10 mM (left
line) or 15 mM (right line)]. Where indicated, medium was removed after treatment with ChoKa inhibitors and changed for fresh medium with 5.5 mM
5-FU for an additional 24 h. Protein expression was analyzed by western blot using monoclonal anti-phospho p44/p42 MAPK and anti-p44/p42
MAPK. The figure shows a representative blot of two independent experiments. (B) SW620 cells were grown and treated as indicated in (A) with
15 mM MN58b and 5.5 mM 5-FU alone or in combination for 24 hours. Protein expression was analyzed by western blot using anti-pAKT- Ser473, anti-
AKT or anti-GAPDH. The figure shows on the top a representative blot, at the bottom protein levels (pAKT-Ser473/total AKT/GAPDH) from a
representative experiment. (C) 26106 SW620 cells were seeded in p100 plates and incubated 24 h under standard conditions. Cells were then treated
with 15 mM MN58b and 5.5 mM 5-FU alone or in combination for 24 hours. Total ceramide levels were analyzed by UPLC-TOF. Mean 6 SD of two
independent experiments performed in triplicate are shown.
doi:10.1371/journal.pone.0064961.g010
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conditions. P53 and K-Ras status were considered as previously
described [51–53]. MN58b or TCD-717 were added at different
concentrations from stocks solutions. After treatment with ChoKa
inhibitors, medium was removed and replaced with fresh medium
containing 5-FU. Quantification of the number of cells remaining
in each well was carried out by the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) method. Absorbance is
read at 560 nm in a VersaMax Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA).
Chemicals
MN58b was dissolved in sterilized H2O; TCD-717 was
dissolved in DMSO: H2O (v/v, 2:1), the source of both drugs is
Medicinal Chemistry Department, University of Granada, Spain.
5-FU was purchased from Sigma Chemical Co. and reconstituted
in PBS. Stock solutions were prepared at 5 mM.
Combined effect evaluation
Drug interaction between ChoKa inhibitors and 5-FU was
assessed using the combination index (CI) [28] where CI,1,
CI= 1 and CI.1 indicate synergistic, additive or antagonistic
effects respectively. The CI value was calculated according to the
formula CI = (D1/(Df)1+ D2/(Df)2), where (Df)1 is the concen-
tration of MN58b or TCD-717 and (Df)2 the concentration of 5-
FU respectively, required to inhibit cell growth x% and D1 and D2
are the drugs concentrations in combination treatment that also
inhibit cell growth by x%. Data analysis was performed by the
Calcusyn software (Biosoft, Oxford, UK).
Flow cytometric assay
Cell cycle distribution was determined by DNA content analysis
after propidium iodide (PI) staining. Cells were treated with
ChoKa inhibitors and 5-FU alone or in combination for 48 h.
Cells were then harvested, stained and incubated with detergent
and 1 ml of PI (50 mg/ml). The DNA content of approximately
46105 stained cells was analyzed using a Coulter XL-MZL flow
cytometer. The fraction of cell death, G0-G1, S and G2-M phases
were analyzed by DNA program software Multicycle AV for
Windows de Phoenix Flow Systems.
Tumor xenograft studies
All experiments concerning living laboratory animals were
performed after protocol approval by a local ethical committee,
following Spanish Laboratory Animal. Female athymic BALB/C
nude mice were supplied by Jackson Laboratories (Bar Harbor,
Maine 04609 USA). MN58b and 5-FU were dissolved in PBS and
injected i.p. in amounts of 0.1 ml/mouse. TCD-717 was dissolved
in DMSO: H2O 2:1, and diluted with PBS to the appropriate
concentration.
Mice were inoculated subcutaneously with injections of 16106
DLD-1 cells in each flank of the mouse mixed with matrigel
(354234, BD Bioscience) 1:1. Tumor sizes were determinate using
micrometer calipers and when the size of the tumors was
approximately 0.2 cm3, mice were divided into four groups:
control group; MN58b 2 mg/kg/3 days group; 5-FU 40 mg/kg/2
days group and MN58b plus 5-FU combination group during 3
weeks. The experiment was repeated following a similar protocol
with TCD-717 2 mg/kg/3 days in DLD-1 and SW620.
Western blot analysis
Cells were incubated with ChoKa inhibitors and 5-FU single or
in combination. Same amounts of protein (30 mg) were loading
into SDS-PAGE acrylamide gels and resolved proteins were
transferred onto nitrocellulose membranes. The following anti-
bodies were used: monoclonal anti thymidylate synthase (TS)
TS106 clone (MAB 4130 Millipore), monoclonal anti thymidine
kinase (TK1) F12 clone (Sigma, SAB1406531), polyclonal anti
PARP (Santa Cruz Biotechnology, sc-7150), polyclonal anti
caspase-3 (Cell Signaling, #9662), monoclonal anti ChoKa,
polyclonal anti-E2F1, clones KH20 y KH95 (Millipore, 05-379),
monoclonal anti-phospho p44/p42 MAPK (Cell Signaling
#9106), monoclonal anti p44/p42 MAPK (Cell Signaling
#4695), monoclonal anti pAKT (Ser473) (Cell Signaling
#4051s), and monoclonal anti AKT (Cell Signaling #2920s).
Monoclonal anti GAPDH (Millipore, MAB374) and monoclonal
anti a-tubulin (Sigma T9026) were used as loading controls.
siRNA Transfection
46105 HT29 and SW620 cell lines were transfected using
LipofectamineTM 2000 (Invitrogen) following the manufacturer’s
instructions. siRNA targeting ChoKa was purchased from Qiagen
(SI03063942) and non-targeting control (scr) was purchased from
Ambion (AM4635). HT29 and SW620 cells were seeded in 6 wells
plates. 24 h later cells were transfected with a ChoKa specific
siRNA or a control siRNA (scr) during 24 h in medium OPTI-
MEM and then, medium was removed and changed for medium
with serum. Proteins were extracted 48 h later. Protein expression
was analyzed by Western blot using ChoKa monoclonal antibody,
polyclonal antibody anti-PARP or polyclonal antibody anti
caspase-3. Monoclonal antibody anti a-tubulin or monoclonal
antibody anti GAPDH were used as loading controls.
Quantitative real-time reverse transcription-PCR analysis
Cells were incubated for 24 h with ChoKa inhibitors. Total
RNA was extracted using RNeasy Mini kit (Qiagen). 1 mg of RNA
was used to generate cDNA using High-Capacity cDNA Archive
Kit (Applied Biosystems), and quantitative real-time PCR was
carried out in triplicate using the ABI PRISM 7700 Sequence
Detector (Applied Biosystems). 18S ribosomal RNA was amplified
as internal control. Probes used for amplification were from
Applied Biosystems as Taqman Gene Expression Assays
Hs00426591_m1 for TS, Hs01062125_m1 for TK1,
Hs00427695_m1 for UPP1 and 14319413E for 18S.
Caspase activity assay
Caspase-3 enzymatic activity was determined using Caspase-3
Fluorometric Assay Kit (R&D Systems, Inc. Minneapolis MN),
according to manufacturer’s protocol. HT29 cells were seeded in
60 mm dishes at 56105 cells/dish and treated with MN58b or
vehicle for 24 h and then lysed for the assay. Alternatively, cells
were transfected with siRNA targeting ChoKa or a control (scr)
siRNA as described above and then lysed for the assay.
Ceramide analysis by UPLC-MS
SW620 cells were seeded at a density of 26106 cells per p100
plate. Twenty-four hours later, cells were treated with MN58b and
5-FU alone or in combination for 24 hours. Then, cells were
washed in PBS and collected by brief trypsinization. Sphingolipid
extracts, fortified with internal standards (N-dodecanoylsphingo-
sine, N-dodecanoylglucosylsphingosine, D-erythro-dihydrosphin-
gosine, N-dodecanoylsphingosylphosphorylcholine, and C17D-
erythro-dihydrosphingosine-1-phosphate, 0.2 nmol each), were
prepared and analyzed by ultraperformance liquid chromatogra-
phy, coupled to high-resolution electrospray ionization time-of-
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flight mass spectrometry (UPLC-TOF; Waters, Milford, MA,
USA).
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Figure S1 Plots obtained by Calcusyn program when
ChoKa inhibitors, TCD-717 and MN58b, are combined
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1, HT29 and SW620. Graphs represent combination indexes
(CI). Numbers represents different experiments exposed in the
table below each figure.
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